Theratechnologies (TSE:TH) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theratechnologies has announced a potential early 2025 supply disruption for EGRIFTA SV due to a voluntary shutdown at their contract manufacturer’s facility, following FDA inspection. The company is working with the FDA to resume production and mitigate patient impact, with a projected revenue shortfall of US$1.6 million for the fiscal year 2024.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.